[Sodium dantrolene (dantrium) in the treatment of neurogenic muscular spasm].
Forty patients, whose ages varied from 4 to 65 years, presenting skeletal muscle spascitiy as sequel of cerebral palsy, spinovertebral trauma and cerebral vascular diseases were treated with Dantrium (dantrolene sodium), a drug muscle relaxing. Laboratory data included: electromiography, chronaximetry, EEG and blood and urine tests. Clinical followup revealed subjective improvement in the patients and also objective decrease of spasticity in a satisfactory number. Patients who had improvement with this therapy also had no beneficial results with other drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002547:Cerebral Palsy / Q000150:complications; D002561:Cerebrovascular Disorders / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003620:Dantrolene / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D013119:Spinal Cord Injuries / Q000150:complications
D006827:Hydantoins; D003620:Dantrolene
El dantroleno sódico (Dantrium) en el tratamiento del espasmo muscular neurogénico